Verona Pharma PLC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Verona Pharma provides employees with an update on the integration process with Merck, detailing retention agreements, severance, and the preliminary integration timeline.
Verona Pharma plc has filed a supplement to its definitive proxy statement, updating details on executive severance benefits, management arrangements, and the expiration of the HSR waiting period related to its Scheme of Arrangement.
Verona Pharma has entered into a definitive agreement to be acquired by Merck Sharp & Dohme LLC for $107 in cash per American Depositary Share, representing a significant premium to recent trading prices.
Merck & Co. Inc. is moving forward with the potential acquisition of Verona Pharma PLC, emphasizing employee retention and the strategic importance of Ohtuvayre.
Merck announced its intent to acquire Verona Pharma, integrating Verona's ensifentrine, a novel COPD treatment, into its portfolio, with ongoing clinical trials expected to continue uninterrupted.
Merck & Co., Inc. detailed its strategic rationale and integration plans for Verona Pharma, emphasizing the significant opportunity to address unmet needs in Chronic Obstructive Pulmonary Disease (COPD) with Ohtuvayre.
Merck has reached a definitive agreement to acquire Verona Pharma PLC for approximately $10 billion, valuing Verona's American Depositary Shares at $107 each, with the transaction expected to close in the fourth quarter of 2025.
Merck announced a definitive agreement to acquire Verona Pharma for approximately $10 billion, adding Ohtuvayre, a recently FDA-approved COPD maintenance treatment, to its growing cardio-pulmonary pipeline.
Verona Pharma convenes its Annual General Meeting on April 24, 2025, to address director re-elections, executive compensation, and share allotment authorizations following the FDA approval and commercial launch of Ohtuvayre.
Verona Pharma's Annual General Meeting will take place on April 26, 2024, to vote on director re-elections, auditor appointments, executive compensation, and share allotment authorizations.